BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease
Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease appeared first on MedCity News.
Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications.
The post BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease appeared first on MedCity News.
